Epilepsy and migraine market Target opportunity centers on EpaleX’s inhaled antiseizure therapy for epilepsy and refractory migraines, presenting a strong case for neurology-focused partnerships, investigator-sponsored trials, and hospital formulary discussions.

Early-stage funding With current funding around a few million dollars and revenue in the low millions, there is a window for strategic alliances with larger pharma or contract manufacturing to scale manufacturing, distribution, and co-development while de-risking capital needs.

Small team leverage A lean organization (2–10 employees) can benefit from channel partnerships, contract research and manufacturing, or distribution agreements to accelerate market entry and regulatory support without a large in-house expansion.

Health tech stack fit Leverage digital capability and data partnerships around patient adherence, real-world evidence, and telehealth integration using EpaleX’s tech stack to demonstrate value for payors and healthcare providers.

Adjacent medical devices Position the pocket nebulizer as a gateway to a broader inhaled therapy platform, exploring collaborations with device makers, inhalation technology suppliers, and specialty clinics treating epilepsy comorbidities and refractory migraine.